patient
admit
intens
care
unit
icu
requir
administr
one
blood
compon
stay
patient
exhibit
great
divers
condit
necessit
care
icu
age
underli
medic
problem
integr
physiolog
compensatori
mechan
patient
howev
share
need
optim
oxygencarri
capac
tissu
perfus
ongo
blood
loss
result
injuri
surgic
wound
invas
monitor
equip
blood
sampl
requir
coupl
inadequ
marrow
function
red
cell
destruct
make
red
cell
transfus
necess
mani
icu
patient
addit
mani
patient
suscept
develop
hemostat
disord
requir
administr
blood
compon
plasma
cryoprecipit
platelet
concentr
blood
compon
consid
drug
exert
potent
therapeut
respons
yet
also
capabl
caus
signifi
cant
advers
effect
food
drug
administr
fda
regul
blood
compon
prepar
test
administr
unlik
pharmaceut
agent
howev
blood
compon
fewer
object
indic
use
therapeut
index
relat
dose
safeti
simpl
monitor
effi
caci
continu
need
blood
compon
determin
blood
level
drug
addit
risk
associ
transfus
known
advanc
may
lethal
risk
includ
medic
error
well
infecti
immunolog
hazard
unlik
pharmaceut
agent
prescrib
product
requir
document
patient
consent
indic
use
although
american
blood
suppli
safer
ever
zerorisk
transfus
achiev
even
blood
compon
could
steril
process
donor
select
screen
becom
increasingli
stringent
evolut
began
respons
welldefi
ned
risk
transfusiontransmit
hepat
human
immunodefi
cienci
viru
hiv
infect
although
valu
maxim
recipi
safeti
unargu
increas
donor
select
price
test
ad
condit
place
donor
number
usabl
donat
declin
trend
led
occasion
region
season
blood
shortag
rare
outright
inabl
provid
certain
blood
compon
clinician
prescrib
blood
compon
must
awar
uncertainti
avail
contribut
use
blood
product
appropri
nation
blood
bank
system
seek
strategi
ensur
adequ
safe
blood
suppli
donor
screen
strategi
ensur
recipi
safeti
take
sever
form
american
blood
donor
voluntari
donor
cash
payment
elimin
studi
link
profession
donor
transmiss
hepat
confi
dential
questionnair
initi
limit
transmiss
hiv
hepat
allow
voluntari
selfexclus
involuntari
exclus
donor
pose
increas
risk
transmit
infecti
agent
multipl
specifi
c
serolog
biochem
test
perform
detect
potenti
transmiss
hiv
retrovirus
hepat
syphili
donor
indic
highrisk
behavior
test
repeatedli
posit
place
perman
deferr
list
patient
may
insist
blood
obtain
rel
friend
practic
term
direct
design
donat
select
donor
must
undergo
rigor
question
test
volunt
donor
studi
found
increas
frequenc
hepat
marker
blood
direct
donor
compar
blood
drawn
unselect
volunt
other
suggest
design
donor
may
differ
new
volunt
continu
consensu
whether
direct
donor
group
safe
volunt
donor
institut
polici
accept
process
direct
donat
vari
wide
case
support
icu
patient
requir
largevolum
transfus
direct
donat
unlik
advantag
practic
basic
principl
blood
compon
therapi
prescript
specifi
c
blood
product
need
meet
patient
requir
singl
whole
blood
wb
donat
separ
composit
part
compon
distribut
sever
recipi
differ
physiolog
need
compon
therapi
thu
meet
clinic
requir
increas
safeti
efficaci
conserv
limit
resourc
varieti
blood
product
compon
increas
howev
complex
transfus
medicin
also
increas
wb
donat
typic
separ
red
blood
cell
rbc
platelet
concentr
fresh
frozen
plasma
ffp
within
hour
collect
plasma
may
process
cryoprecipit
supernat
cryopoor
plasma
one
unit
wb
measur
approxim
ml
includ
ml
citrat
anticoagulantpreserv
solut
unit
wb
suppli
ml
rbc
ml
plasma
volum
replac
wb
refriger
day
depend
preserv
use
less
hour
refriger
storag
preserv
bag
system
platelet
granulocyt
function
lost
storag
level
labil
coagul
factor
v
viii
decreas
blood
center
offer
modifi
ed
wb
produc
remov
platelet
cryoprecipit
fraction
return
supernat
plasma
red
cell
permit
provis
labil
compon
patient
specifi
c
need
remaind
form
product
composit
essenti
coldstor
wb
howev
grow
need
special
blood
compon
result
process
major
blood
donat
compon
thu
limit
avail
wb
modifi
ed
wb
rbc
common
usag
pack
red
cell
prbc
blood
compon
commonli
transfus
increas
red
cell
mass
prbc
deriv
centrifug
sediment
wb
remov
plasmaanticoagul
solut
collect
citratephosphatedextroseadenin
solut
volum
approxim
ml
hematocrit
hct
storag
life
day
extend
addit
solut
permit
storag
day
increas
volum
ml
decreas
hct
extend
storag
unit
commonli
use
easier
transfus
lower
viscos
may
pose
problem
larger
volum
transfus
leukocytereduc
rbc
may
benefi
certain
patient
transfus
blood
compon
contain
leukocyt
may
lead
febril
reaction
greater
propens
alloimmun
platelet
alloimmun
transmiss
pathogen
carri
leukocyt
cytomegaloviru
cmv
leukocyt
reduct
defi
ned
fda
requir
fi
ltration
blood
compon
special
fi
lter
filtrat
may
perform
either
time
blood
donat
process
later
time
transfus
bedsid
fi
ltration
filtrat
storag
convey
benefi
remov
white
blood
cell
wbc
deterior
elabor
cytokin
unwant
substanc
storag
proven
theoret
benefi
ts
leukocyt
reduct
blood
compon
discuss
later
section
cover
advers
effect
transfus
mani
european
countri
canada
requir
transfus
leukocyt
reduc
process
call
univers
leukoreduct
ulr
institut
unit
state
also
made
decis
either
method
leukocyt
reduct
add
signifi
cantli
cost
transfus
benefi
ts
measur
appli
global
yet
quantifi
ed
wash
prbc
involv
recentrifug
remov
plasmapreserv
solut
unit
howev
wash
may
take
hour
limit
subsequ
storag
time
caus
loss
rbc
wash
also
effect
method
leukoreduct
indic
use
wash
rbc
although
recipi
plasma
reaction
may
benefi
prbc
frozen
cryoprotect
solut
store
extend
period
frozen
rbc
gener
limit
unit
special
valu
rare
rbc
antigen
profi
le
autolog
blood
donat
need
store
futur
use
raredonor
registri
frozen
prbc
exist
assist
provid
blood
patient
complex
multipl
alloantibodi
red
cell
antigen
signifi
cant
advanc
plan
necessari
acquir
thaw
frozen
prbc
transfus
thu
limit
use
acut
situat
wb
prbc
suffer
cell
loss
storag
current
technolog
bag
preserv
solut
attempt
optim
cell
qualiti
quantiti
use
strict
criteria
determin
length
allow
storag
time
nonetheless
red
cell
metabol
decreas
progress
storag
lesion
result
accumul
varieti
undesir
substanc
loss
cellular
function
time
storag
slow
rise
concentr
potassium
lactat
aspart
aminotransferas
lactat
dehydrogenas
ammonia
phosphat
free
hemoglobin
slow
decreas
ph
bicarbon
concentr
occur
cytokin
infl
ammatori
mediat
tumor
necrosi
factor
also
accumul
ph
freshli
store
blood
citrat
solut
declin
approxim
end
unit
shelf
life
potassium
leak
red
cell
storag
level
high
meql
may
result
howev
unit
transfus
suppli
meq
potassium
well
toler
circumst
storag
period
also
progress
decreas
rbcassoci
adenosin
triphosph
atp
decreas
increas
affi
niti
hemoglobin
oxygen
shift
oxygen
dissoci
curv
left
decreas
oxygen
deliveri
tissu
littl
evid
howev
transient
increas
oxygen
affi
niti
clinic
import
infus
gradual
increas
transfus
red
cell
circul
recoveri
hour
full
replac
hour
decreas
atp
storag
diminish
viabil
red
cell
transfus
one
chief
factor
limit
storag
time
current
avail
storag
rejuven
solut
optim
cellular
constitu
major
blood
transfus
form
prbc
compon
indic
normovolem
patient
intravascular
volum
constraint
necessari
use
wb
may
desir
patient
requir
increas
oxygencarri
capac
volum
resuscit
larg
ongo
hemorrhag
howev
avail
wb
gener
limit
resuscit
effect
achiev
use
prbc
crystalloid
solut
unit
prbc
wb
expect
rais
hemoglobin
level
gdl
hct
stabl
nonbleed
averages
adult
although
studi
demonstr
slight
superior
fresh
wb
compon
use
cardiac
surgeri
select
patient
benefi
ts
fresh
blood
remain
controversi
current
test
process
requir
limit
gener
avail
despit
long
tradit
transfus
rbc
critic
ill
patient
precis
indic
transfus
remain
sourc
controversi
specifi
c
transfus
practic
may
vari
wide
among
clinician
major
random
studi
rbc
transfus
polici
survey
transfus
practic
show
half
icu
patient
receiv
red
cell
transfus
anoth
show
icu
stay
longer
week
rate
transfus
total
number
transfus
high
icu
practic
character
high
rate
transfus
reason
controversi
clear
rbc
transfus
enhanc
tissu
oxygen
deliveri
underli
physiolog
anemia
complex
adapt
anemia
potenti
advantag
disadvantag
particular
group
patient
well
understood
compensatori
mechan
acut
chronic
anemia
divers
complex
work
concert
maintain
oxygen
within
microcircul
cardiovascular
adjust
lead
increas
cardiac
output
includ
decreas
afterload
increas
preload
result
chang
vascular
tone
increas
myocardi
contractil
elev
heart
rate
lower
blood
viscos
permit
improv
fl
ow
erythrocyt
within
capillari
blood
fl
ow
redistribut
favor
critic
organ
higher
oxygen
extract
pulmonari
mechan
though
contribut
rel
littl
shortterm
oxygen
demand
exert
potent
effect
relat
metabol
variabl
final
hemoglobin
molecul
undergo
biochem
conform
chang
enhanc
unload
oxygen
capillari
level
mechan
contribut
oxygen
reserv
capac
exce
baselin
requir
approxim
fourfold
experiment
model
exist
encompass
divers
physiolog
compens
hypoxia
experi
carri
anim
case
report
patient
refus
transfus
indic
extrem
low
hct
toler
tissu
perfus
adequ
certain
object
though
indirect
measur
tissu
oxygen
exist
avail
clinician
care
patient
monitor
invas
icu
mix
venou
oxygen
content
pv
cardiac
output
measur
patient
undergo
pulmonari
arteri
catheter
arteri
oxygen
content
also
measur
directli
oxygen
extract
ratio
er
calcul
directli
presenc
normal
high
cardiac
output
measur
tissu
oxygen
extract
indirectli
adequaci
tissu
oxygen
deliveri
total
bodi
er
baselin
fall
pv
er
increas
greater
propos
indic
need
red
cell
transfus
random
trial
transfus
polici
icu
larg
enough
draw
specifi
c
statist
signifi
cant
conclus
canadian
critic
care
trial
group
compar
liber
target
hemoglobin
gdl
restrict
target
hemoglobin
gdl
red
cell
transfus
polici
patient
stratifi
ed
diseas
sever
day
random
restrict
strategi
least
good
better
p
liber
strategi
overal
hospit
mortal
signifi
cantli
lower
restrict
strategi
group
p
patient
younger
year
patient
lower
apach
acut
physiolog
age
chronic
health
evalu
ii
score
restrict
strategi
clearli
superior
addit
liber
transfus
associ
shorter
icu
stay
less
organ
failur
shorter
hospit
stay
longer
mechan
ventil
time
cardiac
event
frequent
liber
strategi
group
later
subgroup
analysi
patient
cardiovascular
diseas
though
small
enough
statist
doubt
suggest
liber
transfus
strategi
probabl
appropri
patient
sever
ischem
coronari
diseas
observ
support
experiment
studi
effect
anemia
laboratori
anim
coronari
occlus
canadian
studi
highlight
mani
complex
issu
involv
transfus
decis
make
icu
sinc
public
canadian
studi
sever
larg
report
examin
use
red
cell
transfus
critic
care
unit
vincent
colleagu
survey
european
icu
found
transfus
rate
patient
icu
stay
stay
mean
pretransfus
hemoglobin
level
g
dl
corwin
colleagu
studi
icu
unit
state
year
later
found
great
similar
nearli
patient
receiv
transfus
mean
threshold
hemoglobin
level
gdl
singl
larg
scottish
teach
hospit
report
parsimoni
practic
rate
transfus
still
icu
patient
total
volum
blood
use
slightli
smaller
mean
pretransfus
hemoglobin
level
gdl
author
conclud
icu
practic
fulli
embrac
guidelin
canadian
clinic
trial
contrast
hospit
australia
new
zealand
report
transfus
consecut
icu
admiss
although
author
found
median
pretransfus
hemoglobin
concentr
gdl
rate
transfus
lower
patient
bleed
inappropri
transfus
rate
author
specul
practition
may
infl
uenc
public
canadian
studi
region
survey
transfus
practic
nonetheless
agre
full
implement
canadian
guidelin
clinic
set
might
controversi
literatur
rbc
transfus
set
surgeri
particularli
surgeri
use
blood
product
grow
mount
bodi
data
illustr
human
toler
low
hct
surgeri
recent
random
trial
rbc
transfus
strategi
orthoped
surgeri
demonstr
signifi
cant
differ
outcom
restrict
gdl
liber
gdl
transfus
threshold
includ
monitor
silent
myocardi
ischemia
preoper
postop
provid
adequ
perfus
microcircul
maintain
purpos
mainten
low
hct
surgeri
techniqu
call
normovolem
hemodilut
power
tool
minim
blood
loss
attend
need
red
cell
transfus
tabl
summar
guidelin
propos
nation
institut
health
american
societi
anesthesiologist
american
colleg
physician
rel
transfus
rbc
guidelin
provid
intent
establish
paramet
intent
substitut
individu
clinician
judgment
art
medic
decis
make
transfus
area
medicin
lie
determin
appropri
treatment
individu
patient
platelet
concentr
randomdonor
platelet
obtain
centrifug
unit
donat
wb
unit
contain
minimum
platelet
suspend
ml
plasma
platelet
store
room
temperatur
avoid
loss
function
refriger
constantli
agit
maxim
ga
exchang
length
storag
vari
contain
use
system
permit
storag
limit
storag
time
increas
demand
compon
platelet
often
subject
suppli
shortag
loss
viabil
platelet
number
occur
storag
platelet
still
effect
hemostasi
bag
enter
pool
transfus
platelet
must
administ
within
hour
unit
platelet
expect
increas
platelet
count
l
typic
adult
usual
dose
unit
kg
bodi
weight
posttransfus
platelet
count
obtain
determin
adequaci
respons
follow
equat
relat
platelet
number
bodi
size
posttransfus
increment
use
assess
effect
transfus
abocompat
platelet
desir
essenti
abomismatch
platelet
given
remov
incompat
plasma
carri
time
pool
transfus
likewis
volum
reduct
may
necessari
patient
risk
fl
uid
overload
ml
plasma
present
unit
platelet
nonetheless
remain
plasma
good
sourc
stabl
coagul
factor
contain
diminish
still
potenti
benefi
cial
amount
factor
v
viii
contraind
use
rhposit
platelet
rhneg
patient
given
women
futur
childbear
potenti
rh
immun
globulin
rhig
may
use
prophylact
small
risk
rh
alloimmun
red
cell
may
contain
platelet
concentr
plateletpheresi
common
term
singledonor
platelet
apheresi
platelet
involv
separ
remov
platelet
one
donor
cytapheresi
procedur
autom
devic
retransfus
remaind
blood
back
donor
collect
contain
equival
unit
platelet
concentr
singledonor
platelet
suspend
ml
plasma
abo
volum
consider
discuss
earlier
pertain
singledonor
platelet
offer
clear
benefi
reduc
risk
multipledonor
exposur
recipi
singledonor
platelet
may
also
avail
altern
recipi
alloimmun
previou
platelet
transfus
may
human
leukocyt
antigen
hla
platelet
antigen
match
recipi
use
apheresi
platelet
exce
use
pool
randomdonor
platelet
howev
use
product
emerg
situat
limit
avail
volunt
donor
platelet
transfus
indic
patient
bleed
thrombocytopenia
function
platelet
defect
guidelin
transfus
continu
evolv
current
guidelin
mere
provid
desir
rang
platelet
count
assum
normal
platelet
function
tabl
ampl
evid
bleed
medic
surgic
patient
platelet
count
l
benefi
transfus
thrombocytopenia
abnorm
critic
invas
procedur
even
small
amount
bleed
could
lead
loss
vital
organ
function
death
maintain
platelet
count
l
greater
typic
prefer
presenc
factor
diminish
platelet
function
certain
drug
foreign
intravascular
devic
eg
intraaort
balloon
pump
membran
oxygen
infect
uremia
may
alter
requir
upward
patient
risk
small
strateg
import
hemorrhag
neurosurg
patient
may
need
maintain
count
l
patient
without
hemorrhag
platelet
count
l
lower
appear
increas
risk
signifi
cant
hemorrhag
indic
transfus
patient
count
l
less
well
establish
thu
major
guidelin
propos
prophylact
platelet
transfus
prevent
hemorrhag
threshold
l
bleed
time
use
procedur
situat
usual
prolong
count
l
may
insuffi
cientli
reproduc
correl
poorli
risk
bleed
patient
undergo
cardiac
bypass
surgeri
experi
drop
platelet
count
often
acquir
transient
platelet
function
defect
damag
associ
bypass
apparatu
patient
experi
plateletassoci
bleed
howev
prophylact
transfus
absenc
bleed
warrant
patient
continu
bleed
postop
like
caus
local
surgic
correct
lesion
failur
revers
heparin
condit
exclud
empir
transfus
platelet
may
justifi
ed
patient
thrombocytopen
virtu
immunolog
destruct
process
idiopath
thrombocytopen
purpura
itp
receiv
littl
benefi
platelet
transfus
transfus
platelet
rapidli
remov
circul
event
lifethreaten
hemorrhag
extens
surgic
procedur
transfus
may
prove
benefi
cial
shortterm
effect
transfus
may
accomplish
effect
pretreat
highdos
immunoglobulin
highdos
antid
antiserum
rhig
platelet
transfus
report
deleteri
thrombot
thrombocytopen
purpura
ttp
relat
hemolyticurem
syndrom
heparininduc
thrombocytopenia
cautiou
administr
case
lifethreaten
thrombocytopen
bleed
prudent
prophylact
platelet
transfus
thrombocytopenia
secondari
underproduct
remain
controversi
common
practic
transfus
maintain
platelet
count
l
deriv
data
publish
demonstr
increas
spontan
bleed
leukem
patient
level
howev
critic
evalu
data
reveal
seriou
hemorrhag
greatli
increas
count
fell
l
lower
patient
receiv
aspirin
fever
might
compromis
platelet
function
enhanc
bleed
somewhat
recent
studi
quantit
stool
blood
loss
aplast
anemia
patient
defi
ned
bleed
threshold
platelet
count
l
prospect
studi
conserv
transfus
protocol
found
major
bleed
episod
occur
day
count
less
l
day
count
l
trigger
prophylact
platelet
transfus
l
rang
howev
appli
primarili
stabl
thrombocytopen
patient
factor
fever
use
anticoagul
antiplatelet
drug
invas
procedur
must
consid
gener
treatment
plan
individu
patient
patient
experienc
rapid
drop
platelet
count
may
greater
risk
steadi
state
thu
may
benefi
transfus
higher
count
benefi
ts
patient
judici
use
platelet
transfus
includ
decreas
donor
exposur
lessen
risk
transfusiontransmit
diseas
fewer
febril
allerg
reaction
may
complic
hospit
cours
potenti
delay
prevent
alloimmun
hla
platelet
antigen
develop
refractori
platelet
transfus
seriou
event
herald
fall
cci
poor
respons
platelet
transfus
seen
patient
reason
platelet
consumpt
includ
splenomegali
fever
trauma
crush
injuri
burn
dissemin
intravascular
coagul
dic
concomit
drug
transfus
platelet
substandard
qualiti
factor
sought
correct
possibl
alloimmun
character
develop
antihla
plateletspecifi
c
antibodi
result
immun
platelet
destruct
mani
patient
receiv
multipl
red
cell
platelet
transfus
becom
immun
leukocyt
deplet
transfus
compon
prevent
delay
phenomenon
import
use
leukoreduc
compon
earli
cours
transfus
therapi
patient
fail
achiev
expect
increment
platelet
transfus
provis
abospecifi
c
platelet
concentr
less
hour
old
may
improv
respons
improv
seen
aforement
medic
condit
exclud
patient
screen
hla
antibodi
hla
type
provid
hlacompat
singledonor
platelet
altern
platelet
crossmatch
patient
serum
carri
advantag
unmatch
singledonor
platelet
situat
standard
ffp
prepar
centrifug
wb
frozen
within
hour
blood
donat
ffp
may
store
frozen
year
usual
volum
ml
depend
donor
hct
common
method
thaw
transfus
soak
c
water
bath
requir
minut
thaw
ffp
store
refriger
maximum
hour
prepar
store
manner
ffp
suppli
constitu
amount
normal
present
circul
plasma
includ
stabl
labil
coagul
factor
complement
albumin
globulin
convent
coagul
factor
present
concentr
uml
crossmatch
recipi
perform
ffp
must
abo
compat
standard
ffp
like
transmit
hepat
hiv
transfusionrel
infect
cellular
compon
new
ffp
product
recent
introduc
respons
concern
transmiss
infecti
diseas
one
product
solventdetergenttr
ffp
solventdeterg
treatment
mean
viral
inactiv
remov
infect
lipidenvelop
virus
hepat
b
c
hiv
product
deriv
pool
plasma
mani
donor
lot
potenti
actual
increas
recipi
exposur
pathogen
inactiv
solventdeterg
method
hepat
parvoviru
vulner
newli
emerg
nonlipidenvelop
agent
varieti
techniqu
reduc
pathogen
exposur
ffp
develop
includ
exposur
low
ph
vapor
heat
treatment
ultraviolet
irradi
gamma
irradi
psoralen
light
inactiv
pathogen
induc
dna
damag
none
ffp
product
entir
free
risk
diseas
transmiss
advers
effect
infectionreduc
modifi
cation
add
significantli
cost
compon
ffp
use
judici
administ
provid
coagul
factor
plasma
protein
obtain
safer
sourc
ffp
commonli
use
treat
bleed
patient
acquir
defi
cienci
multipl
coagul
factor
liver
diseas
dic
dilut
coagulopathi
treat
patient
congenit
defi
cienci
coagul
factor
protein
concentr
safer
sourc
exist
ffp
may
indic
emerg
revers
coagulopathi
induc
warfarin
anticoagul
concentr
product
avail
provis
protein
c
patient
defi
cient
suffer
acut
thrombosi
ffp
administ
bolus
rapidli
feasibl
result
factor
level
allow
hemostasi
use
ffp
infus
without
adequ
bolu
administr
help
ffp
use
volum
expans
wound
heal
nutrit
sourc
protein
ffp
revers
anticoagul
induc
heparin
theori
might
exacerb
bleed
suppli
antithrombin
heparin
cofactor
prophylact
administr
ffp
improv
patient
outcom
set
massiv
transfus
cardiac
surgeri
unless
bleed
associ
document
coagul
abnorm
patient
usual
bleed
result
coagul
factor
insuffi
cienci
intern
normal
ratio
inr
less
even
result
alway
predict
partial
thromboplastin
time
ptt
use
predict
procedur
bleed
risk
ffp
often
request
prophylact
invas
procedur
patient
exhibit
mild
prolong
coagul
studi
procedur
may
carri
safe
without
transfus
ffp
ffp
probabl
misus
blood
compon
illustr
retrospect
survey
coagul
factor
normal
present
blood
far
excess
minimum
level
requir
hemostasi
littl
normal
plasma
concentr
sever
factor
effect
hemostasi
convers
ffp
treatment
acquir
multipl
defi
cienci
hepat
failur
often
ineffect
mani
patient
toler
infus
volum
requir
achiev
hemostat
level
coagul
factor
even
transient
plasma
halflif
transfus
factor
vii
hour
may
imposs
administ
suffi
cient
ffp
everi
hour
without
encount
intravascular
volum
overload
final
instanc
transfus
seemingli
adequ
volum
may
still
fail
correct
coagulopathi
care
document
need
ffp
adequaci
outcom
therapi
essenti
cryoprecipit
manufactur
thaw
centrifug
ffp
c
resuspend
precipit
protein
ml
supernat
plasma
bag
concentr
sourc
factor
viii
unit
von
willebrand
factor
vwf
origin
plasma
content
fi
brinogen
mg
factor
xiii
origin
plasma
content
fi
bronectin
cryoprecipit
offer
advantag
transfus
specifi
c
protein
less
total
volum
equival
dose
ffp
use
treat
patient
inherit
coagulopathi
hemophilia
von
willebrand
diseas
factor
xiii
defi
cienci
critic
care
set
commonli
use
replenish
fi
brinogen
especi
bleed
patient
hypofi
brinogenemia
caus
dilut
consumpt
coagulopathi
cryoprecipit
also
reportedli
improv
hemostasi
urem
patient
presum
revers
function
platelet
defect
desmopressin
acet
ddavp
conjug
estrogen
exert
similar
effect
use
preferenti
avoid
potenti
transfusiontransmit
diseas
usual
dose
cryoprecipit
treat
hypofi
brinogenemia
bagsunit
start
bagsunit
everi
hour
necessari
keep
fi
brinogen
level
mgdl
bagunit
cryoprecipit
carri
risk
diseas
transmiss
equival
unit
blood
reason
commerci
factor
viii
concentr
recombin
treat
inactiv
virus
prefer
cryoprecipit
treat
hemophilia
patient
immun
serum
globulin
ig
rhig
hyperimmun
globulin
diseas
hepat
b
varicella
zoster
obtain
fraction
pool
plasma
follow
chromatographi
delipid
step
remov
aggreg
infecti
agent
intraven
ig
ivig
avail
solut
lyophil
form
protein
content
vari
mode
prepar
avail
product
vari
slightli
amount
iga
igm
contain
mostli
present
trace
quantiti
ig
prepar
use
provid
passiv
antibodi
prophylaxi
suppli
ig
certain
immunodefici
state
hyperimmun
globulin
may
use
treat
activ
infect
immunosuppress
host
recent
applic
exploit
ig
immunomodulatori
effect
treat
wide
varieti
disord
immun
basi
specifi
c
mechan
action
ivig
condit
yet
identifi
ed
possibl
includ
interfer
macrophag
fc
receptor
function
neutral
antiidiotyp
antibodi
interfer
incorpor
activ
complement
fragment
immun
complex
recent
review
complet
discuss
effect
ivig
immun
system
potenti
use
rhig
prepar
pool
plasma
obtain
donor
sensit
red
cell
antigen
rh
group
standarddos
vial
contain
primarili
igg
antid
protein
content
ml
dose
protect
ml
red
cell
ml
wb
rhig
carri
risk
viru
transmiss
although
rhig
use
primarili
obstetr
may
also
indic
prevent
alloimmun
rhneg
patient
receiv
small
amount
rhposit
red
cell
platelet
concentr
routin
prophylaxi
larg
number
red
cell
unit
rhposit
wb
prbc
given
accid
rhneg
recipi
reliabl
usual
involv
administr
larg
amount
instanc
effect
use
circumst
report
higher
dose
intraven
rhig
use
treatment
itp
plasmaderiv
colloid
includ
human
serum
albumin
hsa
avail
solut
plasma
protein
fraction
ppf
avail
solut
deriv
pool
donor
plasma
essenti
pathogenfre
hsa
compos
least
albumin
wherea
ppf
subject
fewer
purifi
cation
step
contain
least
albumin
correspondingli
globulin
solut
isooncot
wherea
solut
hsa
hyperoncot
requir
infus
crystalloid
solut
potenti
clinic
indic
colloid
solut
includ
hypovolem
shock
hypotens
associ
hypoproteinemia
patient
liver
failur
proteinlos
condit
replac
solut
plasma
exchang
exchang
transfus
facilit
diuresi
fl
uidoverload
hypoproteinem
patient
albumin
solut
indic
nutrit
sourc
rais
serum
albumin
use
indic
particularli
resuscit
becom
controversi
pulmonari
edema
report
associ
infus
although
albumin
solut
reason
safe
product
administ
expens
limit
avail
restrict
use
anaphylact
reaction
report
less
recipi
use
ppf
associ
sever
hypotens
episod
hageman
factor
fragment
prekallikrein
activ
demonstr
thu
make
ppf
less
desir
resuscit
fl
uid
contraind
cardiac
surgeri
granulocyt
concentr
transfus
obtain
singl
donor
cytapheresi
method
gener
involv
administr
hydroxyethyl
starch
corticosteroid
donor
improv
granulocyt
yield
granulocyt
colonystimul
factor
gcsf
ad
collect
regimen
increas
cell
count
granulocyt
surviv
substanti
collect
contain
least
granulocyt
suspend
approxim
ml
plasma
signifi
cant
number
red
cell
present
crossmatch
recipi
requir
potenti
risk
graftversushost
diseas
gvhd
granulocyt
usual
collect
hlamatch
donor
granulocyt
store
room
temperatur
must
transfus
within
hour
collect
although
sooner
better
rapid
deterior
cell
patient
may
benefi
granulocyt
transfus
includ
neutropen
absolut
neutrophil
count
less
l
unrespons
appropri
antibiot
treatment
bone
marrow
recoveri
expect
occur
cours
therapi
gener
involv
daili
infus
day
granulocyt
use
progress
fungal
infect
immunosuppress
granulocytopen
patient
patient
defect
leukocyt
eg
chronic
granulomat
diseas
neonat
icu
neonat
sepsi
random
trial
suggest
granulocyt
transfus
circumst
reduc
mortal
trial
conduct
decad
effect
antibiot
regimen
signifi
cant
advers
effect
associ
use
granulocyt
concentr
includ
pulmonari
insuffi
cienci
relat
alloimmun
cmv
infect
limit
use
recent
year
decis
transfus
blood
compon
like
therapeut
maneuv
must
made
full
awar
potenti
risk
recipi
well
expect
benefi
ts
public
expect
zerorisk
blood
suppli
help
rais
acuiti
physician
decis
patient
benefi
transfus
obviou
associ
risk
pale
comparison
consequ
withhold
transfus
howev
clinician
knowledg
incid
manag
advers
reaction
transfus
vital
ensur
best
patient
care
also
provid
appropri
patient
educ
true
inform
consent
almost
everi
patient
receiv
allogen
blood
transfus
experi
advers
reaction
univers
effect
immunomodul
bone
marrow
suppress
consid
measur
reaction
transfus
occur
patient
seriou
advers
respons
may
expect
transfus
natur
advers
reaction
rang
common
clinic
unimport
may
caus
signifi
cant
morbid
death
tabl
transfus
icu
common
often
lightli
regard
event
howev
sign
symptom
sever
lifethreaten
reaction
frequent
indistinguish
troublesom
less
signifi
cant
reaction
everi
transfus
patient
experi
signifi
cant
chang
condit
elev
temperatur
chang
puls
blood
pressur
dyspnea
pain
must
promptli
fulli
evalu
identifi
caus
reaction
institut
treatment
necessari
basic
approach
acut
reaction
maintain
high
index
suspicion
acut
hemolyt
reaction
stop
transfus
immedi
maintain
venou
access
intraven
fl
uid
inform
blood
bank
laboratori
immedi
appropri
transfus
reaction
protocol
stitut
posttransfus
specimen
obtain
earli
recognit
sever
transfus
reaction
may
lifesav
fear
reaction
blood
transfus
intravascular
hemolysi
caus
recipi
complementfi
xing
antibodi
attach
donor
rbc
result
rbc
lysi
abo
incompat
often
implic
incid
intravascular
hemolysi
still
singl
common
acut
caus
fatal
associ
transfus
episod
addit
hemolysi
complement
activ
stimul
releas
infl
ammatori
mediat
cytokin
therebi
lead
hypotens
vascular
collaps
activ
coagul
system
may
result
dic
acut
renal
failur
may
also
occur
presum
basi
immun
complex
interact
morbid
mortal
directli
relat
quantiti
incompat
blood
transfus
prompt
recognit
cessat
transfus
overemphas
misidentifi
cation
patient
cleric
error
time
begin
process
specimen
acquisit
releas
unit
initi
infus
major
caus
acut
intravascular
hemolysi
reaction
like
occur
critic
care
set
icu
oper
room
emerg
depart
anywher
els
hospit
far
prefer
transfus
uncrossmatch
group
red
cell
chanc
abo
incompat
caus
improp
patient
specimen
identifi
cation
procedur
common
clinic
sign
hemolysi
fever
without
chill
common
sign
symptom
includ
back
fl
ank
pain
anxieti
nausea
lightheaded
dyspnea
hemodynam
instabl
comatos
anesthet
patient
mani
symptom
evid
therefor
sign
hypotens
hemoglobinuria
diffus
ooz
punctur
site
incis
may
notabl
featur
immedi
manag
hemolyt
transfus
reaction
must
includ
cessat
transfus
remaind
care
support
rapid
verifi
cation
patient
unit
identifi
cation
must
made
confi
rm
suspect
reaction
also
prevent
second
patient
receiv
reciproc
incompat
unit
cleric
error
made
desir
end
point
support
care
includ
mainten
blood
pressur
high
urin
output
support
coagulopathi
blood
loss
steroid
heparin
specifi
c
pharmacolog
intervent
role
treatment
anaphylact
reaction
blood
transfus
fortun
rare
may
lifethreaten
usual
caus
recipi
antibodi
compon
plasma
patient
lack
commonli
antibodi
iga
igadefi
cient
individu
sign
symptom
includ
sever
malais
anxieti
fl
ush
dizzi
dyspnea
bronchospasm
abdomin
pain
vomit
diarrhea
hypotens
eventu
shock
fever
hemolysi
occur
manag
includ
immedi
cessat
transfus
standard
therapi
anaphylaxi
antiiga
antibodi
determin
caus
reaction
patient
must
receiv
blood
compon
donat
igadefi
cient
individu
unavail
special
prepar
wash
rbc
platelet
concentr
plasmaderiv
prepar
albumin
ig
contain
vari
amount
iga
pose
substanti
risk
patient
febril
nonhemolyt
reaction
fnhr
commonli
occur
immedi
transfus
reaction
reaction
annoy
clinician
patient
transfus
servic
alik
caus
signifi
cant
discomfort
share
certain
manifest
acut
hemolyt
reaction
must
investig
everi
instanc
fnhr
occur
approxim
transfus
episod
etiolog
factor
probabl
complex
multipl
mani
reaction
caus
releas
cytokin
pyrogen
either
within
transfus
unit
blood
result
recipi
antibodi
donor
leukocyt
clinic
sign
includ
fever
without
chill
usual
begin
hour
start
transfus
occasion
delay
hour
multipar
women
patient
multipli
transfus
particularli
prone
fnhr
transfus
must
stop
appropri
transfus
reaction
evalu
institut
antipyret
acetaminophen
may
administ
though
commonli
use
antihistamin
diphenhydramin
neither
prevent
therapeut
acut
hemolysi
exclud
transfus
new
unit
may
institut
patient
experi
second
reaction
repeat
reaction
becom
problemat
leukocytedeplet
blood
compon
may
suppli
implement
ulr
result
reduct
frequenc
fever
seen
transfus
hive
pruritu
rel
common
advers
effect
transfus
hypersensit
reaction
local
skin
caus
unknown
may
includ
donor
recipi
characterist
reaction
consist
local
gener
urticaria
begin
shortli
start
transfus
without
sign
symptom
anaphylaxi
hemolysi
transfus
temporarili
stop
antihistamin
may
administ
hive
resolv
short
time
unit
blood
may
cautious
restart
repeat
urticari
reaction
occur
premed
antihistamin
may
effect
blood
compon
wash
remov
plasma
may
requir
intravascular
volum
overexpans
particularli
like
occur
critic
care
patient
limit
cardiac
reserv
asid
inher
volum
blood
compon
intraven
normal
salin
concurr
administ
add
volum
load
unfortun
normal
salin
solut
intraven
fl
uid
may
administ
blood
compon
care
attent
transfus
requir
use
volum
reduct
maneuv
avail
transfus
servic
volum
overload
minim
instanc
frequenc
complic
transfus
report
delay
hemolysi
uncommon
probabl
underrecogn
reaction
transfus
result
stimul
primari
secondari
anamnest
recipi
antibodi
respons
foreign
rbc
antigen
antibodi
undetect
time
transfus
increas
transfus
manner
analog
vaccin
booster
effect
reaction
typic
occur
day
transfus
unrecogn
lack
clear
tempor
associ
transfus
fever
chill
unexplain
declin
hct
usual
sign
transient
elev
bilirubin
lactat
dehydrogenas
may
also
occur
diagnosi
establish
posit
direct
antiglobulin
coomb
test
result
recipi
antibodi
coat
donor
rbc
antibodi
may
identifi
ed
elut
rbc
demonstr
within
recipi
serum
specifi
citi
antibodi
often
rbc
antigen
rh
famili
kidd
duffi
kell
system
hemolysi
may
occur
like
extravascular
rare
caus
renal
failur
dic
prevent
reaction
diffi
cult
alloimmun
foreign
rbc
antigen
occur
approxim
transfus
detect
delay
antibodi
purpos
requir
new
blood
bank
specimen
everi
hour
patient
recent
transfus
perman
transfus
record
record
occurr
delay
antibodi
even
though
may
appar
later
crossmatch
access
transfus
databas
critic
care
patient
past
histori
transfus
transfusionrel
acut
lung
injuri
trali
uncommon
seriou
advers
effect
transfus
recent
gain
recognit
similar
reaction
call
pulmonari
leukoagglutinin
reaction
noncardiogen
pulmonari
edema
reaction
consist
acut
respiratori
distress
syndrom
ard
develop
hour
transfus
sign
symptom
includ
bilater
pulmonari
infi
ltrate
hypoxemia
fever
occasion
hypotens
monitor
patient
found
normal
low
pulmonari
wedg
pressur
central
venou
pressur
contrast
patient
experienc
volum
overload
adequ
respiratori
support
oxygen
establish
promptli
spontan
resolut
gener
occur
within
day
death
nonetheless
occur
particularli
delay
diagnosi
episod
trali
appear
sever
possibl
caus
mechan
case
may
caus
donor
antibodi
react
recipi
neutrophil
hla
antigen
plasma
factor
relat
blood
storag
also
implic
lipid
substanc
deterior
donor
cell
membran
prime
recipi
neutrophil
damag
pulmonari
vasculatur
lead
increas
capillari
permeabl
ardslik
syndrom
clinic
factor
may
contribut
increas
risk
cardiac
bypass
surgeri
procedur
antibodi
model
least
implic
antibodi
uniqu
donor
affl
ict
recipi
probabl
experi
anoth
reaction
provid
recipi
expos
donor
trali
undoubtedli
underrecogn
critic
care
set
may
frequent
confus
fl
uid
overload
cardiogen
pulmonari
edema
transfusionassoci
gvhd
tagvhd
welldocu
probabl
underrecogn
highli
lethal
immunolog
complic
blood
transfus
immunocompromis
patient
infus
blood
compon
contain
viabl
donor
lymphocyt
risk
engraft
allogen
lymphocyt
ensu
reject
recipi
host
tissu
transfus
recipi
highest
risk
includ
neonat
especi
prematur
bone
marrow
organ
transplant
recipi
leukemia
lymphoma
patient
tagvhd
also
report
patient
cardiac
surgeri
receiv
design
donor
blood
rel
presum
hla
antigen
differ
donor
recipi
insuffi
cient
stimul
recipi
immun
respons
suffi
cient
elicit
donor
immun
respons
onset
tagvhd
usual
within
day
transfus
manifest
fever
rash
follow
diarrhea
evid
liver
bone
marrow
injuri
tagvhd
differ
seen
bone
marrow
transplant
bmt
involv
marrow
far
greater
mortal
treatment
larg
ineffect
mortal
exce
irradi
blood
compon
gy
prevent
tagvhd
elimin
donor
lymphocyt
mitogen
respons
cellular
blood
compon
irradi
transfus
highrisk
patient
function
cellular
compon
blood
unaffect
although
damag
rbc
membran
limit
postirradi
storag
prbc
blood
donat
rel
patient
irradi
hlamatch
crossmatch
platelet
product
allogen
blood
transfus
shown
modul
suppress
recipi
immun
respons
effect
fi
rst
note
kidney
transplant
immunosuppress
critic
care
set
gener
undesir
whether
transfus
signifi
cant
impact
debat
ongo
clinic
issu
center
around
two
area
controversi
put
associ
blood
transfus
increas
number
postop
infect
increas
rapid
rate
tumor
recurr
surgic
oncolog
patient
certain
malign
resolut
either
issu
despit
prospect
trial
perform
largest
prospect
trial
colorect
cancer
resect
exampl
neg
metaanalysi
extant
data
suggest
advers
effect
recurr
exist
similarli
random
trial
postop
critic
care
unit
infect
small
indic
effect
transfus
point
direct
advers
effect
controversi
continu
larger
random
trial
conduct
precis
mechan
immunosuppress
induc
allogen
transfus
yet
delin
sever
mechan
may
involv
alter
identifi
ed
laboratori
clinic
transfus
recipi
includ
depress
thelpertsuppressor
lymphocyt
ratio
decreas
natur
killer
cell
activ
diminish
gener
format
antiidiotyp
antibodi
impair
phagocyt
cell
function
chronic
persist
donor
lymphocyt
microchimer
suggest
lowlevel
gvhd
difficulti
analysi
human
data
aris
patient
requir
blood
transfus
condit
induc
immun
chang
evid
bolster
result
two
larg
clinic
trial
suggest
leukocyt
reduct
blood
compon
reduc
elimin
immunosuppress
effect
propon
viewpoint
argu
reason
ulr
would
benefi
patient
receiv
blood
transfus
lead
fewer
infect
tumor
recurr
relat
put
risk
transfus
potenti
result
save
live
cost
prospect
trial
extrem
import
public
awar
transfusionassoci
acquir
immunodefi
cienci
syndrom
aid
done
revolution
transfus
practic
transfus
risk
result
conserv
blood
use
stringent
donor
select
criteria
improv
screen
test
result
viral
transmiss
rate
diffi
cult
measur
risk
transfusionrel
infecti
diseas
lower
ever
current
best
estim
unit
per
transmit
kind
infect
agent
cmv
epsteinbarr
viru
includ
bacteri
infect
becom
common
infecti
risk
thank
increasingli
sensit
donor
screen
test
includ
nucleic
acid
test
nat
detect
viral
dna
rna
shorten
infecti
period
reduc
risk
posttransfus
hepat
pth
viral
infect
sever
fatal
report
yearli
transfus
blood
compon
contamin
viabl
prolifer
bacteria
without
accumul
endotoxin
platelet
concentr
must
store
room
temperatur
particularli
prone
bacteri
growth
report
incid
transfus
organ
isol
platelet
implic
fatal
transfus
reaction
includ
staphylococcu
streptococcu
speci
gramneg
bacilli
fatal
result
bacteri
contamin
refriger
rbc
occur
well
often
involv
cryophil
bacteria
rbc
transfus
contamin
yersinia
enterocolitica
consist
report
decad
transfus
reaction
caus
bacteri
endotoxin
contamin
fortun
quit
rare
mortal
exce
sign
symptom
reaction
caus
microbi
contamin
overlap
hemolyt
transfus
reaction
consist
primarili
fever
hypotens
along
sign
endotox
shock
recogn
promptli
gram
stain
implic
unit
prepar
immedi
posit
appropri
antibiot
support
therapi
institut
autolog
blood
compon
may
also
contamin
time
collect
therefor
reaction
occur
patient
receiv
blood
dismiss
instead
evalu
fulli
though
patient
receiv
allogen
blood
success
viral
screen
measur
clearli
illustr
fall
risk
pth
past
decad
although
pth
continu
signifi
cant
caus
morbid
mortal
natur
pth
chang
year
stepwis
institut
variou
donor
screen
measur
elimin
paid
donor
success
introduct
immunolog
test
hepat
b
result
steadi
reduct
rate
pth
caus
hepat
b
viru
hbv
approxim
per
million
unit
transfus
blood
product
although
hbv
transmiss
result
acut
hepat
chronic
hbv
infect
develop
less
patient
contrast
risk
chronic
hepat
c
viru
hcv
infect
transfus
higher
nearli
longterm
risk
cirrhosisor
hepatocellular
carcinomarel
mortal
year
pth
secondari
hcv
clinic
cours
hepat
gener
milder
lack
chronic
carrier
state
mean
donor
screen
symptom
acut
ill
risk
transmiss
much
lower
estim
less
one
million
unit
preval
hepat
b
surfac
antigenemia
among
fi
rsttime
blood
donor
preval
hepat
c
antibodi
donor
approxim
time
given
sensit
current
screen
assay
includ
latest
gener
enzym
immunoassay
eia
nat
current
risk
pth
result
hcv
believ
less
although
hbv
still
implic
pth
attribut
seroneg
window
period
newli
infect
donor
risk
transfusionassoci
hepat
b
unit
retrovirus
rnabas
virus
character
revers
transcriptas
integr
host
genom
lentivirus
subset
retrovirus
ubiquit
anim
initi
identifi
ed
human
earli
known
capabl
transmiss
transfus
human
tcell
leukemialymphoma
viru
htlv
ii
transfusionassoci
aid
initi
report
late
fi
rst
report
associ
viral
agent
appear
late
march
screen
enzymelink
immunosorb
assay
elisa
detect
antibodi
licens
immedi
incorpor
bloodscreen
process
improv
confi
dential
donor
screen
appear
decreas
risk
infecti
unit
appear
donor
pool
discoveri
heat
treatment
reduc
transmiss
result
reduct
transmiss
plasma
product
especi
person
hemophilia
clinic
aid
develop
recipi
infect
blood
product
vast
major
succumb
diseas
remov
donor
unit
seroposit
elisa
insuffi
cient
prevent
transmiss
sever
hundr
case
report
annual
introduct
elisa
test
subsequ
develop
assay
antigen
nat
lower
risk
transfusionassoci
infect
less
one
million
see
tabl
despit
donor
screen
sensit
assay
includ
eia
nat
antigen
extrem
small
fi
nite
risk
transmiss
screen
blood
transfus
remain
risk
larg
due
seroneg
window
period
experienc
newli
infect
donor
estim
averag
day
second
retroviru
fi
rst
describ
resid
countri
west
africa
subsequ
detect
migrant
western
europ
caus
immunodefici
syndrom
similar
caus
although
case
report
unit
state
report
transfusiontransmit
case
experi
retrovirus
suggest
screen
may
prevent
major
potenti
transmiss
therefor
donat
blood
screen
assay
presenc
antibodi
retroviru
htlvi
caus
agent
adult
tcell
leukemia
atl
strongli
implic
chronic
progress
neurolog
disord
term
tropic
spastic
paraparesi
htlviassoci
myelopathi
tspham
htlvii
link
hairi
cell
leukemia
transfusiontransmit
case
report
viru
exhibit
strong
serolog
crossreact
htlvi
screen
assay
fail
distinguish
antibodi
either
viru
transfusiontransmit
htlvi
demonstr
tspham
develop
small
percentag
infect
transfus
recipi
transfusionassoci
case
atl
seen
approxim
donor
unit
state
seroposit
htlvi
htlvii
test
reveal
major
htlvii
donat
blood
current
screen
antibodi
htlvi
htlvii
estim
risk
htlv
transmiss
screen
neg
blood
believ
million
cmv
human
herpesviru
establish
latent
infect
host
tissu
particularli
leukocyt
transmit
cellular
blood
compon
seroposit
presenc
antibodi
denot
previou
exposur
viru
confer
protect
immun
secondari
reinfect
reactiv
latent
infect
occur
antibodi
cmv
persist
life
serv
marker
indic
potenti
transmiss
live
viru
immunocompet
recipi
transfus
cmvposit
blood
experi
minim
morbid
mortal
major
asymptomat
wherea
heterophileneg
mononucleosi
syndrom
may
develop
immunocompromis
patient
howev
may
suffer
lifethreaten
manifest
sever
interstiti
pneumon
gastroenter
hepat
dissemin
diseas
sever
group
patient
particular
risk
box
patient
receiv
blood
incap
transmit
viru
patient
may
benefi
cmvneg
blood
well
seroneg
solid
organ
transplant
recipi
autolog
bmt
patient
screen
donat
blood
cmv
routin
done
perform
quickli
necessari
preval
donor
seroposit
quit
high
region
cmvseroneg
blood
may
readili
avail
blood
leukocyt
deplet
cmv
safe
may
effect
seroneg
blood
prevent
cmv
transmiss
although
recent
metaanalysi
clinic
trial
compar
two
method
suggest
cmvneg
blood
product
might
slight
advantag
leukocytedeplet
product
mani
bloodborn
parasit
may
transmit
transfus
although
rare
occurr
unit
state
donor
screen
question
low
endem
implic
agent
chang
immigr
pattern
worldwid
travel
howev
make
transfusiontransmit
parasit
increas
concern
worldwid
basi
malaria
import
transfusiontransmit
infect
organ
although
three
case
occur
unit
state
year
infect
manifest
delay
fever
chill
seroneg
pregnant
women
seroneg
prematur
infant
weigh
less
g
seroneg
allogen
autolog
bone
marrow
transplant
recipi
seroneg
transplant
recipi
seroneg
organ
diaphoresi
hemolysi
often
mask
underli
medic
condit
fatal
occur
babesiosi
tickborn
diseas
endem
region
unit
state
especi
northeast
seropreval
transfusiontransmit
case
report
asplen
immunocompromis
patient
particularli
suscept
increas
number
latin
american
immigr
unit
state
american
trypanosomiasi
chaga
diseas
endem
latin
american
countri
emerg
potenti
pathogen
parasit
diseas
transmit
transfus
includ
toxoplasmosi
leishmaniasi
lyme
diseas
parvoviru
recogn
pathogen
capabl
transmiss
transfus
typic
clinic
fi
nding
potenti
sever
hematolog
complic
case
epsteinbarr
viru
infect
typic
mononucleosislik
ill
report
transfus
west
nile
viru
also
transmit
transfus
infl
uenza
sever
acut
respiratori
syndrom
sar
new
viral
infect
capabl
transmiss
transfus
although
case
report
preval
asymptomat
diseas
unknown
rise
area
concern
transmiss
prion
diseas
either
jacobcreutzfeldt
diseas
bovin
spongiform
encephalopathi
bse
donor
referr
criteria
implement
diseas
transmiss
bse
report
unit
kingdom
massiv
transfus
defi
ned
administr
blood
compon
excess
one
blood
volum
within
period
averag
adult
kg
repres
approxim
unit
wb
equival
prbc
crystalloid
solut
compon
massiv
transfus
especi
rang
unit
blood
product
caus
complic
gener
seen
usual
transfus
practic
accumul
undesir
substanc
present
within
bank
blood
dilut
deplet
normal
blood
constitu
lack
store
unit
trauma
victim
surgic
patient
undergo
extens
procedur
patient
vascular
coagul
disord
may
massiv
transfus
critic
care
set
surviv
massiv
transfus
episod
determin
natur
degre
patient
injuri
medic
condit
transfus
presenc
advers
effect
massiv
transfus
complic
patient
cours
icu
transfus
larg
quantiti
store
blood
defi
cient
function
platelet
often
result
hemostat
defect
outright
thrombocytopenia
circul
platelet
consist
decreas
invers
proport
amount
blood
administ
hemostat
signifi
cant
level
l
reach
u
function
defect
also
note
bleed
time
prolong
despit
laboratori
chang
sever
diffus
bleed
develop
less
massiv
transfus
patient
laboratori
studi
predict
prophylact
platelet
transfus
shown
benefi
platelet
count
may
return
hemostat
effect
level
quickli
patient
normal
marrow
function
current
resuscit
massiv
bleed
patient
often
accomplish
prbc
combin
crystalloid
solut
result
hemodilut
normal
plasma
factor
level
transfus
unit
factor
level
effect
normal
hemostasi
realiti
howev
crystalloid
may
given
excess
prbc
unit
transfus
less
plasma
protein
may
remain
bleed
unlik
prothrombin
time
pt
inr
ptt
prolong
exceed
time
midpoint
normal
rang
equival
inr
approach
platelet
prophylact
administr
ffp
prove
effect
prevent
diffus
bleed
thu
decis
transfus
made
individu
basi
determin
presenc
bleed
unaccept
risk
patient
document
abnorm
coagul
one
new
area
controversi
treatment
patient
massiv
hemorrhag
use
recombin
activ
factor
vii
new
agent
creat
treatment
hemophiliac
patient
high
titer
antibodi
factor
viii
make
unabl
benefi
transfus
recombin
factor
viii
activ
factor
vii
bypass
problem
bind
tissu
factor
directli
activ
thrombin
henc
gener
fi
brin
extrem
expens
short
halflif
carri
risk
induc
patholog
thrombosi
potenti
grave
consequ
nevertheless
numer
case
report
new
agent
appear
potenti
benefi
cial
use
earli
resuscit
massiv
injur
patient
unfortun
unsupervis
use
also
result
thrombot
complic
rel
lack
success
suggest
care
control
clinic
trial
appropri
blood
preserv
solut
contain
excess
citrat
anticoagul
store
blood
bind
ioniz
calcium
wb
contain
approxim
g
citratecitr
acid
per
unit
plasma
fraction
patient
normal
liver
function
metabol
citrat
load
unit
wb
minut
hepat
impair
may
extend
remov
minut
longer
toxic
may
result
citrat
administ
excess
metabol
rate
therebi
caus
decreas
ioniz
calcium
level
although
paresthesia
cramp
myoclonu
accompani
citrat
excess
chief
danger
hypocalcemia
depress
myocardi
contractil
potenti
prolong
qt
interv
effect
citrat
transient
use
prbc
contain
littl
residu
citrat
plasma
far
common
massiv
transfus
wb
routin
administr
calcium
indic
clinic
signifi
cant
rebound
hypercalcemia
may
result
calcium
infus
limit
hypoperfus
patient
hepat
cardiac
failur
manifest
citrat
toxic
care
monitor
essenti
potassium
leak
rbc
storag
meq
extracellular
potassium
may
accumul
unit
howev
danger
level
potassium
rare
develop
adult
store
blood
potassium
level
like
determin
patient
acidbas
statu
studi
massiv
transfus
patient
demonstr
wide
rang
potassium
level
hypokalemia
seen
frequent
hyperkalemia
mani
physiolog
mechan
alter
resuscit
includ
respiratori
renal
cardiac
hepat
system
imposs
predict
net
effect
massiv
transfus
serum
potassium
level
ph
bank
blood
drop
storag
time
collect
low
sever
week
storag
administr
larg
quantiti
acid
blood
togeth
metabol
acidosi
common
patient
resuscit
would
lead
one
expect
worsen
acidosi
outcom
massiv
transfus
howev
patient
like
exhibit
metabol
alkalosi
end
transfus
episod
partli
improv
tissu
perfus
metabol
citrat
lactat
bicarbon
patient
renal
failur
may
unabl
handl
bicarbon
load
requir
dialysi
acidosi
persist
transfus
suggest
inadequ
tissu
perfus
empir
administr
bicarbon
counter
acid
load
warrant
may
contribut
deleteri
effect
hypercapnia
patient
impair
ventil
discuss
previous
level
rbcassoci
bank
blood
declin
storag
increas
affi
niti
hemoglobin
oxygen
therebi
result
decreas
oxygen
offload
tissu
even
massiv
transfus
patient
diffi
cult
document
clinic
impact
shift
reliabl
method
restor
red
cell
develop
wb
prbc
store
approxim
c
requir
minut
warm
room
temperatur
elect
transfus
standard
fl
ow
rate
toler
without
need
warm
blood
howev
core
bodi
temperatur
measur
esophag
probe
fall
c
lower
administr
larg
volum
cold
blood
period
hour
advers
effect
hypothermia
includ
decreas
heart
rate
myocardi
contractil
cardiac
arrhythmia
increas
affi
niti
hemoglobin
oxygen
result
decreas
tissu
oxygen
deliveri
dic
impair
abil
metabol
citrat
load
store
blood
blood
warmer
patient
warm
may
institut
massiv
transfus
patient
core
temperatur
monitor
resuscit
effort
whether
massiv
transfus
caus
ard
anoth
sourc
controversi
certainli
theoret
reason
massiv
transfus
might
precipit
ard
cellular
transfus
contain
damag
activ
wbc
cell
membran
aggreg
platelet
microthrombi
capabl
lodg
damag
pulmonari
capillari
despit
possibl
neither
microfi
ltration
transfus
routin
leukocyt
deplet
shown
signifi
cant
impact
incid
ard
massiv
transfus
patient
certainli
caus
ard
exist
patient
undergo
massiv
transfus
possibl
volum
overload
trali
consid
evalu
patient
hypoxia
diffus
pulmonari
infi
ltrate
massiv
transfus
manag
patient
support
consist
overal
manag
massiv
transfus
autoimmun
hemolyt
anemia
patient
autoimmun
hemolyt
anemia
aiha
autoantibodi
usual
broad
specifi
citi
fi
xe
rbc
trigger
extravascular
immunemedi
destruct
patient
aiha
posit
direct
antiglobulin
test
dat
commonli
known
coomb
test
vari
degre
molysi
autoantibodi
caus
agglutin
rbc
donor
crossmatch
hemolysi
brisk
patient
may
requir
red
cell
transfus
support
oxygen
need
medic
manag
aiha
effect
henc
transfus
diffi
cult
agglutin
crossmatch
interfer
proper
defi
nition
compat
unit
rbc
transfus
rbc
subject
immun
hemolysi
host
rbc
mani
blood
bank
method
deplet
autoantibodi
recipi
plasma
elut
antibodi
rbc
arriv
proper
crossmatch
although
crossmatch
time
consum
gener
avail
emerg
basi
lifesav
criteria
transfus
remain
recipi
rbc
crossmatch
red
cell
antigen
abo
rh
group
red
cell
antigen
antibodi
present
howev
sever
hundr
red
cell
antigen
human
famili
repeat
transfus
recipi
may
becom
alloimmun
antigen
gener
alloimmun
occur
approxim
transfus
preval
alloantibodi
higher
chronic
transfus
rel
immunocompet
patient
especi
african
american
whose
distribut
red
cell
antigen
signifi
cant
variat
white
popul
alloimmun
rate
higher
may
found
chronic
transfus
patient
hemoglobinopathi
receiv
rbc
match
potent
minor
antigen
kell
duffi
lewi
alloimmun
may
present
diffi
culti
crossmatch
blood
point
compat
blood
must
obtain
raredonor
registri
patient
present
unresolv
serolog
problem
alloantibodi
never
precis
identifi
ed
yet
major
blood
avail
transfus
incompat
delay
engend
work
multipl
unidentifi
ed
antibodi
may
unaccept
critic
care
situat
need
oxygencarri
capac
leav
choic
transfus
incompat
blood
behavior
antibodi
laboratori
may
assist
predict
clinic
outcom
incompat
transfus
special
procedur
clearanc
studi
fl
ow
cytometri
vivo
crossmatch
cautiou
administr
small
aliquot
blood
subsequ
observ
serum
urin
evid
hemolysi
use
time
permit
emerg
transfus
type
rhneg
uncrossmatch
blood
gener
reserv
resuscit
trauma
patient
delay
crossmatch
may
lifethreaten
risk
alloimmun
gener
accept
low
even
rhposit
type
rbc
may
use
rate
alloimmun
rh
low
circumst
emerg
transfus
dic
present
clinician
diffi
cult
therapeut
choic
common
disord
critic
ill
patient
may
manifest
sever
hemorrhag
thrombosi
therapi
primarili
direct
allevi
caus
support
patient
support
therapi
includ
transfus
compon
need
correct
bleed
diathesi
caus
consumpt
platelet
fi
brinogen
addit
prbc
restor
oxygencarri
capac
platelet
fi
brinogen
cryoprecipit
use
compon
need
repair
coagulopathi
use
risk
mere
fuel
fi
increas
microthrombosi
dic
heparin
anticoagul
controversi
may
increas
risk
bleed
especi
deplet
factor
replenish
defi
nitiv
clinic
trial
endors
routin
use
heparin
random
trial
compon
coagul
inhibitor
uniformli
neg
gener
use
heparin
antifi
brinolyt
agent
confi
ned
sever
protract
case
dic
cirrhot
patient
fulmin
hepat
failur
varieti
hemostat
disord
complic
transfus
manag
bleed
patient
hepat
synthesi
coagul
factor
may
markedli
diminish
therebi
necessit
replac
ffp
cryoprecipit
pattern
factor
diminut
may
vari
acut
hepat
necrosi
chronic
cirrhosi
associ
hemodynam
alter
may
make
imposs
administ
volum
requir
effect
hemostasi
howev
effect
transient
use
factor
concentr
antifi
brinolyt
agent
may
precipit
thrombosi
activ
fi
brinolysi
decreas
clearanc
activ
factor
may
produc
mimic
chronic
dic
thu
exacerb
factor
defi
cienci
impair
coagul
abnorm
platelet
function
thrombocytopenia
may
contribut
coagulopathi
liver
diseas
concomit
splenomegali
reduc
effect
platelet
transfus
bleed
urem
patient
exacerb
acquir
platelet
defect
part
secondari
dialyz
circul
molecul
solubl
platelet
membran
plateletassoci
vwf
plasma
highmolecularweight
vwf
multim
also
shown
decreas
may
explain
benefi
shown
ddavp
cryoprecipit
shorten
bleed
time
improv
hemostasi
urem
patient
rais
hct
red
cell
transfus
anem
patient
also
shown
shorten
bleed
time
presum
result
blood
vessel
walllaminar
blood
fl
ow
interact
transfus
platelet
absenc
thrombocytopenia
unlik
benefi
transfus
platelet
rapidli
becom
dysfunct
aggress
hemodialysi
wide
accept
method
reduc
platelet
dysfunct
bmt
patient
vulner
sever
infecti
toxic
side
effect
abl
treatment
henc
may
care
critic
care
unit
patient
may
intens
red
cell
platelet
transfus
requir
need
special
product
cmvneg
irradi
blood
compon
blood
bank
problem
uniqu
encount
bmt
need
switch
patient
abo
group
abomismatch
transplant
thu
necessit
exchang
transfus
red
cell
plasmacontain
product
ie
platelet
concentr
differ
abo
type
avoid
hemolysi
donor
recipi
cell
bmt
patient
may
also
manifest
increas
rate
delay
hemolyt
reaction
donor
passeng
lymphocyt
recogn
recipi
transfus
red
cell
antigen
patient
monitor
particularli
close
day
minormismatch
allogen
transplant
aggress
transfus
undertaken
hemoglobin
level
fall
dat
result
becom
posit
safest
transfus
one
given
therefor
altern
blood
compon
therapi
continu
sought
valuabl
adjunct
instanc
possibl
limit
homolog
blood
exposur
appropri
use
pharmacolog
agent
promot
hemostasi
administr
recombin
hematopoiet
growth
factor
biolog
growth
modifi
er
stimul
marrow
hematopoiesi
one
substitut
rbc
transfus
approv
unit
state
polyfl
uorocarbon
oxygen
carrier
signifi
cant
limit
blood
substitut
prepar
explor
clinic
trial
cellfre
hemoglobin
solut
crosslink
polymer
chemic
manipul
prevent
rapid
clearanc
circul
intend
provid
shortterm
oxygencarri
capac
acut
ill
patient
advantag
requir
crossmatch
infect
control
although
propos
product
may
longer
shelflif
easier
transport
drawback
mani
circulatori
halflif
hour
oxygen
dissoci
curv
substitut
also
frequent
favor
either
high
fio
requir
load
molecul
less
like
deliv
oxygen
effici
lower
po
level
hemoglobin
sourc
reclaim
bovin
human
red
cell
unlik
patient
accept
blood
compon
religi
belief
jehovah
wit
accept
type
hemoglobin
solut
one
product
develop
use
recombin
technolog
gener
hemoglobin
hope
solut
may
accept
patient
licens
perfl
uorocarbon
solut
fail
demonstr
util
intravascular
oxygen
carrier
unfavor
oxygen
halfsatur
pressur
oxygen
offload
characterist
fi
nding
limit
applic
region
oxygen
angioplasti
stent
placement
procedur
novel
use
liquid
ventil
involv
ventil
intub
patient
experienc
sever
pulmonari
compromis
superoxygen
perfl
uorocarbon
solut
place
oxygenenrich
air
synthet
vasopressin
analogu
ddavp
increas
plasma
factor
viii
c
promot
releas
vwf
endotheli
store
ddavp
provid
effect
hemostasi
bleed
patient
mild
hemophilia
type
von
willebrand
diseas
use
prophylaxi
patient
undergo
surgeri
ddavp
reportedli
improv
platelet
function
patient
qualit
platelet
disord
associ
uremia
cirrhosi
aspirin
ingest
studi
effi
caci
cardiopulmonari
bypass
procedur
confl
ict
subset
patient
may
benefi
chief
drawback
use
tachyphylaxi
develop
essenti
case
shortterm
repeat
administr
lysin
analogu
acid
tranexam
acid
inhibit
fi
brinolysi
block
bind
plasminogen
plasmin
fi
brin
antifi
brinolyt
agent
may
decreas
bleed
thu
need
homolog
blood
compon
patient
hemophilia
thrombocytopenia
system
fi
brinolysi
novel
effect
use
tranexam
acid
involv
administr
mouthwash
prepar
oral
surgeri
patient
hemophilia
receiv
oral
anticoagul
therapi
seriou
side
effect
agent
system
administ
thrombosi
thu
import
use
appropri
monitor
patient
care
use
aprotinin
natur
occur
bovin
serin
proteas
inhibitor
act
plasma
serin
proteas
plasmin
kallikrein
trypsin
coagul
protein
aprotinin
shown
reduc
blood
loss
patient
undergo
cardiopulmonari
bypass
surgeri
inhibit
fi
brinolysi
prevent
platelet
damag
howev
recent
report
renal
injuri
longterm
mortal
may
mean
end
use
aprotinin
use
extens
liver
transplant
involv
high
blood
loss
repeat
administr
pose
risk
anaphylaxi
renal
dysfunct
time
permit
vitamin
k
prefer
agent
revers
coagulopathi
induc
oral
anticoagul
normal
pt
seen
hour
addit
select
cirrhot
patient
may
exhibit
improv
pt
treat
therapeut
dose
vitamin
k
mani
patient
critic
care
unit
exhibit
prolong
pt
especi
dietari
supplement
limit
broadspectrum
antibiot
therapi
given
vitamin
k
safe
effect
agent
revers
effect
recombin
erythropoietin
epo
dramat
reduc
red
cell
transfus
requir
patient
chronic
renal
failur
epo
also
applic
adjunct
treatment
anemia
prematur
infant
anemia
chronic
diseas
especi
rheumatoid
arthriti
cancer
aid
studi
effi
caci
reduc
periop
red
cell
transfus
requir
increas
yield
predeposit
autolog
blood
stimul
bone
marrow
synthesi
surgeri
shown
benefi
reduc
blood
transfus
although
preoper
plan
autolog
deposit
requir
contrast
probabl
impact
epo
immedi
effi
caci
epo
icu
unproven
await
result
larg
clinic
trial
recombin
growth
factor
granulocytemacrophag
colonystimul
factor
gmcsf
gcsf
stimul
marrow
product
leukocyt
enhanc
sever
differ
granulocyt
macrophag
function
agent
fi
nding
applic
reduc
neutropen
period
bmt
cancer
chemotherapi
increas
leukocyt
count
hypoprolif
marrow
condit
myeloid
growth
factor
replac
granulocyt
transfus
remain
indic
cell
salvag
equip
clinic
use
sever
decad
although
cell
salvag
clearli
capabl
rescu
otherwis
lost
red
cell
full
impact
transfus
poorli
document
cell
salvag
gener
consist
collect
shed
blood
clean
uncontamin
oper
fi
eld
follow
remov
cellular
element
retransfus
patient
cell
salvag
use
intraop
postop
especi
cardiac
surgeri
although
clinic
studi
cell
salvag
mani
fl
aw
overal
success
therapi
reduc
transfus
result
wide
applic
risk
includ
bacteri
contamin
febril
reaction
trigger
dic
coagulopathi
result
dilut
combin
acut
intraop
hemodilut
technolog
also
potenti
cost
save
word
apheresi
deriv
greek
aphairein
take
away
thu
therapeut
hemapheresi
perform
remov
unwant
plasma
constitu
plasmapheresi
blood
cell
cytapheresi
autom
cell
separ
use
centrifug
membran
fi
ltration
remov
concentr
select
blood
element
mani
devic
use
prepar
apheresi
blood
compon
transfus
use
perform
patient
procedur
therapeut
apheresi
often
administ
auspic
transfus
medicin
servic
rapid
remov
plasma
cell
may
fi
nd
sever
applic
intens
care
practic
box
goal
plasmapheresi
plasma
exchang
pe
remov
reduc
level
undesir
plasma
constitu
altern
mean
plasma
replac
suppli
miss
substanc
agent
remov
pe
thought
autoantibodi
neurolog
renal
hematolog
condit
treat
manner
immunomodul
pe
anoth
explan
effect
theori
indirectli
support
equival
effi
caci
ivig
therapi
sever
disord
pe
amelior
hyperviscos
either
excess
igm
macroglobulinemia
excess
ig
multipl
myeloma
effect
tempor
measur
treatment
condit
plasmapheresi
pe
standard
therapi
ttp
unfortun
control
trial
pe
exist
although
anecdot
report
abound
pe
seldom
defi
nitiv
treatment
condit
use
appropri
shortterm
adjunct
medic
modal
kinet
pe
predict
onevolum
exchang
remov
given
plasma
constitu
blood
volum
chang
addit
synthesi
mobil
substanc
occur
two
three
volum
exchang
remov
respect
highli
proteinbound
intravascularli
concentr
substanc
effi
cientli
remov
wherea
substanc
larg
volum
distribut
igg
activ
synthesi
larg
extravascular
store
remov
less
predict
rate
usual
shortterm
intens
cours
pe
schedul
fi
onevolum
exchang
approxim
l
normals
adult
period
appropri
replac
fl
uid
condit
albuminsalin
mixtur
provid
oncot
support
without
risk
diseas
transmiss
born
ffp
pe
patient
ttp
use
replac
ffp
suppli
plasma
proteas
consum
diseas
side
effect
pe
rel
common
procedur
gener
minor
relat
vascular
access
temporari
discomfort
vasomotor
symptom
patient
death
rare
due
procedur
larg
cardiopulmonari
caus
plasma
protein
coagul
factor
immunoglobulin
complement
remov
pe
laboratori
test
result
coagul
electrolyt
may
derang
hour
pe
clinic
bleed
rare
observ
coagul
factor
fall
hemostat
level
recov
within
hour
except
fi
brinogen
may
requir
sever
day
complet
replenish
leukapheresi
may
requir
urgent
reduc
wbc
count
patient
acut
myeloid
lymphoblast
leukemia
chronic
myelogen
leukemia
peripher
count
l
greater
procedur
expect
drop
count
third
effect
short
live
leukapheresi
reserv
use
adjunct
chemotherapi
patient
pulmonari
cerebr
leukostasi
cytoreduct
chemotherapi
patient
risk
sever
tumor
lysi
syndrom
plateletpheresi
may
benefi
cial
shortterm
therapi
patient
symptomat
thrombocythemia
manifest
cerebr
myocardi
ischemia
pulmonari
emboli
gastrointestin
bleed
procedur
effect
reduct
platelet
count
cytotox
therapi
start
concomitantli
defi
nitiv
treatment
litig
relat
blood
transfus
becom
promin
particularli
epidem
transfusionassoci
aid
state
regul
blood
bank
medic
practic
blood
product
regard
symptomat
hyperviscos
thrombot
thrombocytopen
purpura
neurolog
diseas
myasthenia
gravi
syndrom
uncontrol
system
vascul
critic
endorgan
injuri
symptomat
leukocytosi
symptomat
thrombocythemia
sickl
cell
anemia
crisi
pulmonari
central
nervou
system
manifest
servic
commod
standard
product
liabil
pertain
blood
compon
howev
neglig
cours
prepar
test
transfer
crossmatch
administ
blood
product
still
potenti
caus
legal
action
everi
clinician
order
transfus
must
awar
blood
compon
like
drug
approv
specifi
c
use
indic
clearli
document
medic
record
inform
consent
patient
import
area
potenti
liabil
joint
commiss
accredit
healthcar
organ
jcaho
requir
written
patient
consent
blood
transfus
sinc
constitut
adequ
inform
consent
respons
advis
patient
still
content
element
inform
consent
includ
understand
need
transfus
risk
benefi
ts
altern
includ
risk
undergo
transfus
well
opportun
ask
question
whether
clinician
document
inform
consent
individu
progress
note
patient
record
standard
form
gener
establish
institut
polici
similarli
institut
vari
respect
polici
consent
adult
temporarili
incompet
sedat
patient
icu
compet
adult
patient
may
refus
blood
transfus
jehovah
wit
commonli
religi
reason
case
law
clear
uphold
right
patient
extend
care
given
time
patient
may
becom
incompet
ie
comatos
refus
express
becom
incompet
court
usual
order
lifesav
transfus
minor
except
made
case
emancip
minor
age
reason
state
evok
special
interest
welfar
fetu
order
transfus
pregnant
women
advent
sentinel
event
review
qualiti
manag
procedur
patient
safeti
impact
transfus
practic
well
procedur
patient
identifi
cation
surgic
procedur
includ
devic
bar
code
reader
also
appli
transfus
practic
howev
annual
sentinel
event
review
report
transfus
error
remain
constant
accord
jcaho
record
blood
compon
prescrib
like
drug
appropri
blood
compon
therapi
requir
specifi
c
blood
product
need
clear
indic
prescrib
avoid
formula
approach
red
blood
cell
transfus
increas
oxygencarri
capac
transfus
decis
base
individu
patient
physiolog
major
patient
hemoglobin
level
greater
gl
requir
transfus
unless
limit
cardiopulmonari
reserv
activ
bleed
platelet
transfus
indic
patient
bleed
thrombocytopenia
function
platelet
defect
guidelin
platelet
transfus
also
conserv
prophylact
platelet
transfus
remain
controversi
warrant
mani
situat
fresh
frozen
plasma
indic
replet
coagul
factor
bleed
patient
defi
cient
factor
provid
specifi
c
plasma
protein
obtain
safer
sourc
cryoprecipit
concentr
sourc
fi
brinogen
select
coagul
factor
cryoprecipit
may
help
correct
hypofi
brinogenemia
dilut
consumpt
coagulopathi
fresh
frozen
plasma
advers
reaction
blood
compon
occur
transfus
episod
adher
routin
protocol
evalu
transfus
reaction
may
save
live
acut
hemolyt
reaction
lead
caus
immedi
transfus
fatal
prevent
reaction
requir
strict
adher
transfus
patient
identifi
cation
procedur
transmiss
infecti
agent
transfus
markedli
reduc
bacteri
infect
common
infecti
complic
transfus
advers
effect
uniqu
massiv
transfus
like
occur
icu
complic
manag
critic
ill
sever
injur
patient
compon
therapi
patient
remain
conserv
emerg
role
activ
factor
vii
treatment
patient
requir
evalu
inform
consent
blood
transfus
standard
practic
compet
adult
legal
right
refus
blood
transfus
consent
critic
ill
patient
remain
subject
individu
institut
polici
